FFIC Flushing Financial Corp

TSC TriState Capital Holdings Inc

CSQPF Cervus Equipment Corp

IMXI International Money Express Inc

MDCO Medicines Co

TVETF Traverse Energy Ltd

Vaxart, Inc., formerly Aviragen Therapeutics, Inc., is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options. Its products include vapendavir, an oral treatment for human rhinovirus (HRV) upper respiratory infections in moderate-to-severe asthmatics in Phase IIb SPIRITUS trial; BTA585, an oral fusion (F) protein inhibitor in Phase II development for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in Phase II development for condyloma caused by human papillomavirus Types 6 and 11. It has preclinical RSV non-fusion inhibitor program. It has focused its research and drug development capabilities on discovering and developing small molecule compounds that can prevent or treat infectious diseases.

New! Enhance the way you research investment opportunities with Social Signals, a one of a kind trading resource that pulls insights from Twitter. Watch the demo video

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.

Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may
expose investors to potentially rapid and substantial losses.Please read Characteristics and Risks of Standard Options before investing in options.